OneSource Specialty Jumps 10% as Q2 Profit Soars 5-Fold to ₹57 Cr on 31.6% Margin
Shares of contract development and manufacturing major OneSource Specialty Pharma witnessed aggressive buying interest on Tuesday, October 27, 2026, surging nearly 10% in opening trade following an exceptional second-quarter earnings performance. The pharma manufacturer posted a more than five-fold increase in consolidated net profit on an annual basis, supported by strong operating leverage where top-line expansion significantly outpaced overhead growth. The company’s net profit escalated to ₹57.4 crore for the quarter ended September 2026, marking a staggering leap from ₹10.4 crore recorded in the corresponding quarter of the previous fiscal year. Total revenue from operations expanded by 37.4% year-on-year to reach ₹516.2 crore compared to ₹376 crore in the year-ago period, driven by the operationalization of new Drug Delivery Device (DDC) capacities, strict execution of commercial manufacturing and supply contracts, and new product launches spanning across its core formulation verticals.
Operating Leverage Expands EBITDA by 53%: Margins Widen to 31.6% on Tight Cost Control
The quarterly scorecard demonstrated sharp operating discipline, with total expenditure rising by 24% to ₹462.5 crore, trailing well behind the 37.4% revenue leap and unlocking substantial bottom-line margins. Consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) surged by 53% year-on-year to ₹163.2 crore against ₹107 crore in the corresponding period last year. Consequently, operating EBITDA margins widened by 320 basis points to 31.6% from 28.4% twelve months prior, translating to an operational cash generation of ₹31.60 for every ₹100 of revenue earned. Outlining the operational milestones achieved during the period, CEO and Managing Director Neeraj Sharma confirmed that the operationalization of newly commissioned DDC facilities provided pivotal revenue support, while the successful commercialization of the company’s second cartridge production line is set to accelerate commercial batches and scale up fill-finish capacity through the second half of the fiscal year. Sharma also highlighted sustained traction within the complex biologics segment, where the company expanded its client base by onboarding another major US-based biotechnology innovator during the quarter.
Stock Surges 10% to ₹1,533 as Dalal Street Prices in Second-Half Biologics Momentum
Dalal Street participants responded decisively to the multi-fold profit expansion and expanding contract book, sending the stock soaring straight out of the gate. Countering broader indices, OneSource Specialty Pharma climbed rapidly from its previous closing benchmark of ₹1,397 to touch an intraday peak of ₹1,533, translating to a single-session gain of close to 10% within the opening hours of trade. The strong market reaction underscores investor confidence in the specialty drugmaker's strategic pivot toward complex drug-device combinations, sterile injectables, and high-margin biologics platforms. With expanded production lines now operating at commercial scale, institutional desks are tracking the company's sustained execution pipeline into the upcoming quarters, as higher capacity utilization and international client additions continue to enhance long-term earnings visibility.
